Cargando…

Efficacy evaluation of surgery combined with chemotherapy for stage IIIA small cell lung cancer patients: a retrospective analysis

BACKGROUND: The efficacy of surgery in combination of chemotherapy for stage IIIA small cell lung cancer (IIIA-SCLC) is controversial. The aim of the present study was to analyze the efficacy of surgery combined with chemotherapy, especially in the setting of neoadjuvant chemotherapy (NAC) followed...

Descripción completa

Detalles Bibliográficos
Autores principales: Bian, Dongliang, Jiang, Siming, Xiong, Yicheng, Qi, Mengfan, Wu, Jiawei, Addeo, Alfredo, Yamauchi, Yoshikane, Manapov, Farkhad, Dempke, Wolfram C. M., Vannucci, Jacopo, Di Federico, Alessandro, Xu, Xiaoxiong, Chen, Linsong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9459616/
https://www.ncbi.nlm.nih.gov/pubmed/36090643
http://dx.doi.org/10.21037/tlcr-22-545
_version_ 1784786553823821824
author Bian, Dongliang
Jiang, Siming
Xiong, Yicheng
Qi, Mengfan
Wu, Jiawei
Addeo, Alfredo
Yamauchi, Yoshikane
Manapov, Farkhad
Dempke, Wolfram C. M.
Vannucci, Jacopo
Di Federico, Alessandro
Xu, Xiaoxiong
Chen, Linsong
author_facet Bian, Dongliang
Jiang, Siming
Xiong, Yicheng
Qi, Mengfan
Wu, Jiawei
Addeo, Alfredo
Yamauchi, Yoshikane
Manapov, Farkhad
Dempke, Wolfram C. M.
Vannucci, Jacopo
Di Federico, Alessandro
Xu, Xiaoxiong
Chen, Linsong
author_sort Bian, Dongliang
collection PubMed
description BACKGROUND: The efficacy of surgery in combination of chemotherapy for stage IIIA small cell lung cancer (IIIA-SCLC) is controversial. The aim of the present study was to analyze the efficacy of surgery combined with chemotherapy, especially in the setting of neoadjuvant chemotherapy (NAC) followed by surgery for IIIA-SCLC. METHODS: Between 2004 and 2015, we reviewed 2,199 chemotherapy-treated stage IIIA (N1/2) SCLC cases in the Surveillance, Epidemiology, and End Results (SEER) database, and 32 NAC + intentional radical resection-treated, centrally-located IIIA-SCLC cases at Shanghai Pulmonary Hospital (SPH). Outcomes were compared between surgically and non-surgically treated patients from the SEER database after propensity score matching (PSM), and comparing lobectomy/bi-lobectomy and pneumonectomy patients from SPH. Prognostic factors were evaluated by Kaplan-Meier method and the Cox proportional hazards regression model. RESULTS: There was significantly higher overall survival (OS) in surgically treated IIIA-SCLC patients (OS, 44.8 vs. 21.2 months, P=0.048), and similar efficacy was observed between sub-lobectomy and lobectomy/bi-lobectomy patients (OS: 55.6 vs. 30.3 months, P=0.167) in SEER database. At SPH, significantly higher OS was associated with T1 stage (before NAC: T1 vs. T2–4, 48.7 vs. 32.2 months, P=0.025; after NAC: T1 vs. T2–4, 42.7 vs. 21.3 months, P=0.048). Female sex [hazard ratio (HR): 0.078, P=0.009], T1 stage (HR: 13.048, P=0.026), and pneumonectomy (HR: 0.095, P=0.009) were independent prognostic factors for IIIA-SCLC patients who received NAC + intentional radical resection. CONCLUSIONS: For stage IIIA SCLC patients, complete resection combined with chemotherapy might improve the prognosis than patients without surgery. Post-NAC lobectomy was not found to be superior to sub-lobectomy, while pneumonectomy was considered suitable for central-type IIIA-SCLC patients after NAC treatment.
format Online
Article
Text
id pubmed-9459616
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-94596162022-09-10 Efficacy evaluation of surgery combined with chemotherapy for stage IIIA small cell lung cancer patients: a retrospective analysis Bian, Dongliang Jiang, Siming Xiong, Yicheng Qi, Mengfan Wu, Jiawei Addeo, Alfredo Yamauchi, Yoshikane Manapov, Farkhad Dempke, Wolfram C. M. Vannucci, Jacopo Di Federico, Alessandro Xu, Xiaoxiong Chen, Linsong Transl Lung Cancer Res Original Article BACKGROUND: The efficacy of surgery in combination of chemotherapy for stage IIIA small cell lung cancer (IIIA-SCLC) is controversial. The aim of the present study was to analyze the efficacy of surgery combined with chemotherapy, especially in the setting of neoadjuvant chemotherapy (NAC) followed by surgery for IIIA-SCLC. METHODS: Between 2004 and 2015, we reviewed 2,199 chemotherapy-treated stage IIIA (N1/2) SCLC cases in the Surveillance, Epidemiology, and End Results (SEER) database, and 32 NAC + intentional radical resection-treated, centrally-located IIIA-SCLC cases at Shanghai Pulmonary Hospital (SPH). Outcomes were compared between surgically and non-surgically treated patients from the SEER database after propensity score matching (PSM), and comparing lobectomy/bi-lobectomy and pneumonectomy patients from SPH. Prognostic factors were evaluated by Kaplan-Meier method and the Cox proportional hazards regression model. RESULTS: There was significantly higher overall survival (OS) in surgically treated IIIA-SCLC patients (OS, 44.8 vs. 21.2 months, P=0.048), and similar efficacy was observed between sub-lobectomy and lobectomy/bi-lobectomy patients (OS: 55.6 vs. 30.3 months, P=0.167) in SEER database. At SPH, significantly higher OS was associated with T1 stage (before NAC: T1 vs. T2–4, 48.7 vs. 32.2 months, P=0.025; after NAC: T1 vs. T2–4, 42.7 vs. 21.3 months, P=0.048). Female sex [hazard ratio (HR): 0.078, P=0.009], T1 stage (HR: 13.048, P=0.026), and pneumonectomy (HR: 0.095, P=0.009) were independent prognostic factors for IIIA-SCLC patients who received NAC + intentional radical resection. CONCLUSIONS: For stage IIIA SCLC patients, complete resection combined with chemotherapy might improve the prognosis than patients without surgery. Post-NAC lobectomy was not found to be superior to sub-lobectomy, while pneumonectomy was considered suitable for central-type IIIA-SCLC patients after NAC treatment. AME Publishing Company 2022-08 /pmc/articles/PMC9459616/ /pubmed/36090643 http://dx.doi.org/10.21037/tlcr-22-545 Text en 2022 Translational Lung Cancer Research. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Original Article
Bian, Dongliang
Jiang, Siming
Xiong, Yicheng
Qi, Mengfan
Wu, Jiawei
Addeo, Alfredo
Yamauchi, Yoshikane
Manapov, Farkhad
Dempke, Wolfram C. M.
Vannucci, Jacopo
Di Federico, Alessandro
Xu, Xiaoxiong
Chen, Linsong
Efficacy evaluation of surgery combined with chemotherapy for stage IIIA small cell lung cancer patients: a retrospective analysis
title Efficacy evaluation of surgery combined with chemotherapy for stage IIIA small cell lung cancer patients: a retrospective analysis
title_full Efficacy evaluation of surgery combined with chemotherapy for stage IIIA small cell lung cancer patients: a retrospective analysis
title_fullStr Efficacy evaluation of surgery combined with chemotherapy for stage IIIA small cell lung cancer patients: a retrospective analysis
title_full_unstemmed Efficacy evaluation of surgery combined with chemotherapy for stage IIIA small cell lung cancer patients: a retrospective analysis
title_short Efficacy evaluation of surgery combined with chemotherapy for stage IIIA small cell lung cancer patients: a retrospective analysis
title_sort efficacy evaluation of surgery combined with chemotherapy for stage iiia small cell lung cancer patients: a retrospective analysis
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9459616/
https://www.ncbi.nlm.nih.gov/pubmed/36090643
http://dx.doi.org/10.21037/tlcr-22-545
work_keys_str_mv AT biandongliang efficacyevaluationofsurgerycombinedwithchemotherapyforstageiiiasmallcelllungcancerpatientsaretrospectiveanalysis
AT jiangsiming efficacyevaluationofsurgerycombinedwithchemotherapyforstageiiiasmallcelllungcancerpatientsaretrospectiveanalysis
AT xiongyicheng efficacyevaluationofsurgerycombinedwithchemotherapyforstageiiiasmallcelllungcancerpatientsaretrospectiveanalysis
AT qimengfan efficacyevaluationofsurgerycombinedwithchemotherapyforstageiiiasmallcelllungcancerpatientsaretrospectiveanalysis
AT wujiawei efficacyevaluationofsurgerycombinedwithchemotherapyforstageiiiasmallcelllungcancerpatientsaretrospectiveanalysis
AT addeoalfredo efficacyevaluationofsurgerycombinedwithchemotherapyforstageiiiasmallcelllungcancerpatientsaretrospectiveanalysis
AT yamauchiyoshikane efficacyevaluationofsurgerycombinedwithchemotherapyforstageiiiasmallcelllungcancerpatientsaretrospectiveanalysis
AT manapovfarkhad efficacyevaluationofsurgerycombinedwithchemotherapyforstageiiiasmallcelllungcancerpatientsaretrospectiveanalysis
AT dempkewolframcm efficacyevaluationofsurgerycombinedwithchemotherapyforstageiiiasmallcelllungcancerpatientsaretrospectiveanalysis
AT vannuccijacopo efficacyevaluationofsurgerycombinedwithchemotherapyforstageiiiasmallcelllungcancerpatientsaretrospectiveanalysis
AT difedericoalessandro efficacyevaluationofsurgerycombinedwithchemotherapyforstageiiiasmallcelllungcancerpatientsaretrospectiveanalysis
AT xuxiaoxiong efficacyevaluationofsurgerycombinedwithchemotherapyforstageiiiasmallcelllungcancerpatientsaretrospectiveanalysis
AT chenlinsong efficacyevaluationofsurgerycombinedwithchemotherapyforstageiiiasmallcelllungcancerpatientsaretrospectiveanalysis